Benzinga | Aug 26, 2020 08:11AM EDT

Avid Bioservices Selected By Mapp Biopharmaceutical, Inc. For Clinical Development Of Novel Human Monoclonal Antiviral Antibody

TUSTIN, Calif., Aug. 26, 2020 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc.(NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced that Mapp Biopharmaceutical, Inc., has contracted Avid to provide process transfer, scale-up and clinical manufacturing services to support one of its development programs for a novel antiviral drug candidate. Avid and Mapp will immediately commence the initial phase of the project.